Unknown

Dataset Information

0

LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases.


ABSTRACT: PURPOSE:HER2?+?breast cancer (BC) is an aggressive subtype with high rates of brain metastases (BCBM). Two-thirds of HER2?+?BCBM demonstrate activation of the PI3K/mTOR pathway driving resistance to anti-HER2 therapy. This phase II study evaluated everolimus (E), a brain-permeable mTOR inhibitor, trastuzumab (T), and vinorelbine (V) in patients with HER2?+?BCBM. PATIENTS AND METHODS:Eligible patients had progressive HER2?+?BCBM. The primary endpoint was intracranial response rate (RR); secondary objectives were CNS clinical benefit rate (CBR), extracranial RR, time to progression (TTP), overall survival (OS), and targeted sequencing of tumors from enrolled patients. A two-stage design distinguished intracranial RR of 5% versus 20%. RESULTS:32 patients were evaluable for toxicity, 26 for efficacy. Intracranial RR was 4% (1 PR). CNS CBR at 6 mos was 27%; at 3 mos 65%. Median intracranial TTP was 3.9 mos (95% CI 2.2-5). OS was 12.2 mos (95% CI 0.6-20.2). Grade 3-4 toxicities included neutropenia (41%), anemia (16%), and stomatitis (16%). Mutations in TP53 and PIK3CA were common in BCBM. Mutations in the PI3K/mTOR pathway were not associated with response. ERBB2 amplification was higher in BCBM compared to primary BC; ERBB2 amplification in the primary BC trended toward worse OS. CONCLUSION:While intracranial RR to ETV was low in HER2?+?BCBM patients, one-third achieved CNS CBR; TTP/OS was similar to historical control. No new toxicity signals were observed. Further analysis of the genomic underpinnings of BCBM to identify tractable prognostic and/or predictive biomarkers is warranted. CLINICAL TRIAL:(NCT01305941).

SUBMITTER: Van Swearingen AED 

PROVIDER: S-EPMC6779035 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Purpose</h4>HER2 + breast cancer (BC) is an aggressive subtype with high rates of brain metastases (BCBM). Two-thirds of HER2 + BCBM demonstrate activation of the PI3K/mTOR pathway driving resistance to anti-HER2 therapy. This phase II study evaluated everolimus (E), a brain-permeable mTOR inhibitor, trastuzumab (T), and vinorelbine (V) in patients with HER2 + BCBM.<h4>Patients and methods</h4>Eligible patients had progressive HER2 + BCBM. The primary endpoint was intracranial response rate  ...[more]

Similar Datasets

| S-EPMC8424223 | biostudies-literature
| S-EPMC3513946 | biostudies-literature
2015-06-25 | E-GEOD-70233 | biostudies-arrayexpress
2015-06-25 | GSE70233 | GEO
| S-EPMC5050126 | biostudies-literature
| S-EPMC6209006 | biostudies-literature
| S-EPMC4189578 | biostudies-literature
| S-EPMC5529768 | biostudies-other
| S-EPMC5140058 | biostudies-literature
| S-EPMC3268553 | biostudies-literature